Latest News Highlights


May 3, 2017: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain.


August 17, 2016: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million.




August 11, 2016: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Company's Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer.




August 4, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas effective July 31, 2015.



Webcast

July 27, 2015: To view the webcast, please click here




July 27, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company's U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo.




June 16, 2015:  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that it has recently completed financing for a total of $850,000 at prices of $1.25-$1.66.




May 15, 2015:  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards.




April 20, 2015:  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today long-term clinical trial results from the Company's NX-1207 prostate cancer study NX03-0040.




April 1, 2015:  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH).




March 31, 2015:  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the year ended December 31, 2014 prepared in accordance with International Financial Reporting Standards.




March 19, 2015:  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today recent private placements of 883,058 shares, with total proceeds of US$400,000.




December 18, 2014:  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today the closing of U.S. $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53.




November 14, 2014:  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2014.




November 2, 2014:  Nymox announced today that the Company’s two Phase 3 U.S. studies of NX-1207 for the treatment of BPH, NX02-0017 and NX02-0018, failed to meet their primary efficacy endpoints.




September 10, 2014:  Nymox announced today new positive outcome results from the Company's ongoing prospective NX03-0040 trial of NX-1207 for the treatment of low grade localized prostate cancer.




June 17, 2014:  Nymox is pleased to announce new data supporting the positive sexual functional preservation profile of NX-1207, the Company's lead compound in Phase 3 development for the treatment of prostate enlargement (BPH or benign prostatic hyperplasia)and Phase 2 development for localized prostate cancer. A detailed study of prostate tissues from men who had received intraprostatic injections of NX-1207 2.5 mg or 15 mg found that nervous tissues in the prostate after treatment were left intact and showed no damage. These new results showing that NX-1207 is nerve-sparing add to the considerable body of evidence that treatment with NX-1207 does not lead to the debilitating sexual side effects often associated with existing prostate treatments.




June 11, 2014:  Nymox is pleased to announce new clinical data supporting the positive safety profile of NX-1207, the Company's lead compound in late Phase 3 testing for prostate enlargement (BPH or benign prostate hyperplasia). Recent pharmacokinetic studies using a newly developed highly sensitive blood test for NX-1207 have shown that the drug is undetectable in the blood post-injection, providing strong evidence that the drug, once injected into the prostate, remains confined to the prostate and thus unable to affect other organs such as the liver, kidneys, heart, or testes.




May 21, 2014:  Nymox is pleased to report new positive data confirming the advantageous side effect profile of the Company's lead compound NX-1207. Results from the Brief Male Sexual Function Questionnaire (BMSF) in the Company's recently completed NX03-0040 trial of NX-1207 2.5 mg and 15 mg for the treatment of low grade localized prostate cancer indicate that targeted treatment with NX-1207 at either dose had no significant effect on reported sexual function score post-treatment.




May 13, 2014:  Nymox reported today positive new study findings showing that the Company’s NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men.




May 6, 2014:  Nymox announced today new positive outcome results from the Company's ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer.




April 30, 2014:  Nymox is pleased to report top-line results from the company's 146 patient NX03-0040 Phase 2 U.S. prostate cancer study. The results from the study indicate an overall benefit in terms of reduced progression in patients with low grade localized (T1c)prostate cancer treated with a single injection of NX-1207 into the area of the prostate where cancer was found. Consistent with earlier clinical trial experience with NX-1207, there were no significant safety issues or side effects associated with the drug in the new study.




March 14, 2014:  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the year ending December 31, 2013.




April 16, 2013:  Nymox reported today positive new study findings which have demonstrated that the Company’s NX-1207 Phase 3 treatment for benign prostatic hyperplasia (BPH or prostatic enlargement) has no detectable effect on key male structures involved in sexual function. This study has provided new data which offers further scientific support of highly selective sparing of prostatic nerves after NX-1207 treatment.




March 27, 2013:  Nymox reported today that the Company’s FDA cleared NicAlert™ product continues to achieve widespread acceptance around the world as an important tool in tobacco-related research studies and programs in a broad range of healthcare areas.




February 19, 2013:  Nymox is pleased to announce its lead drug candidate, NX-1207, has not shown any evidence of eliciting an immune reaction in men treated with intraprostatic injections of the drug. Extensive clinical immunogenicity testing of men in the Company’s pivotal Phase 3 trials (NX02-0017 and NX02-0018) and Phase 3 repeat injection safety study (NX02-0020) showed no evidence of antidrug antibody formation. Periodic safety monitoring reviews of the NX-1207 trials to date have shown no evidence of any allergic reaction to the drug either on first injection or repeat injection.




December 16, 2010: Recordati (Milan: REC.MI) and Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today the signing of a European licensing agreement for the development and commercialization of NX-1207, Nymox’s Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH). Under the terms of the agreement, Recordati receives exclusive rights to develop and subsequently market and sell NX-1207 in Europe including Russia and the CIS, the Middle East, the Maghreb area of North Africa and South Africa (i.e. a total of 81 countries). The licensing agreement covers the use of NX-1207 for the treatment of BPH as the initial indication for development and commercialization. Recordati will make an upfront payment to Nymox of € 10 million (approximately $13 million); approval and sales milestones payments; and tiered supply and royalty payments of a minimum of 26% to increase progressively up to 40% of total net sales in the case specific contractual conditions are achieved. RBC Capital Markets, LLC served as financial advisor.